Dr. Stratton discusses combo of avelumab and BCG in NMIBC

In this video, Kelly L. Stratton, MD, discusses further research on the study, “Novel weekly immunotherapy dosing with avelumab tolerated during Bacillus Calmette-Guerin induction therapy: Initial results of the ABD trial,” presented at the 2021 American Urological Association Annual Meeting, and his take on the current state of BCG-unresponsive non–muscle-invasive bladder cancer. Stratton is an assistant professor of urologic oncology at the University of Oklahoma, Oklahoma City.

Related Videos
Madison Novosel, BA, in an interview with Urology Times
Veda Giri, MD, answers a question during a Zoom video interview
Dr. Bertrand F. Tombal in an interview with Urology Times
Related Content
© 2023 MJH Life Sciences

All rights reserved.